脂肪肝治療薬市場レポート：動向、予測、競合分析 (2030年まで)

脂肪肝治療薬の動向と予測

世界の脂肪肝治療薬市場の将来は、病院・診療所市場での機会により有望視されています。世界の脂肪肝治療薬市場は、2024年から2030年までのCAGRが5.3%で、2030年までに推定263億米ドルに達すると予測されます。この市場の主な促進要因は、アルコール消費の増加と糖尿病の有病率の増加です。

• Lucintel社の予測では、医薬品カテゴリーでは薬剤が予測期間中に最も高い成長を遂げる見込みです。
• 最終用途カテゴリーでは、病院が高い成長を遂げると予測されます。
• 地域別では、生活習慣病の増加とともに薬物乱用やアルコール乱用が増加している北米が予測期間中最大の地域であり続けると思われます。

脂肪肝治療薬市場の戦略的成長機会

脂肪肝治療薬市場全体の主な用途には、複数の戦略的成長機会があります。これらの機会は、治療オプションの進歩、患者の意識の高まり、医療サービスへのアクセスの増加によって支えられています。

• 医薬品の進歩：新規医薬品や併用療法の開発への投資は、優れた成長機会となります。新しい製剤や標的療法は、治療効果の向上や患者にとってより好ましい転帰をもたらす可能性があります。新規医薬品は、市場内のアンメットニーズに対応する新たな治療選択肢を提供し、疾病管理と患者ケアの継続的な改善をサポートすることができます。
• 診断サービスの拡大：画像診断や臨床検査を含む高度な診断に対する需要の高まりは、拡大余地をもたらします。診断ツールの強化により、肥満やアルコールの過剰摂取に関連する他の疾患と同様に、脂肪肝疾患の早期発見と正確なモニタリングが容易になります。診断サービスの利用可能性が高まることで、脂肪肝疾患のより効果的な同定と管理が可能になり、より良い治療計画と患者の転帰の改善が支援されます。
• ライフスタイル/ウェルネス・プログラム：食事療法や運動療法などのライフスタイル/ウェルネス・プログラムを治療計画に組み込むことで、この分野の成長が期待できます。これらのプログラムは治療介入プロセスを助け、一般的な健康増進活動にも貢献します。ライフスタイルやウェルネスプログラムは、患者ケアにより総合的なアプローチを提供し、アドヒアランス率を向上させ、全体的な転帰の改善につながります。
• 遠隔医療とデジタルヘルス：遠隔医療とデジタルヘルスツールの導入により、遠隔モニタリング、患者教育、治療管理の機会が生まれます。これらのソリューションは、アクセシビリティと患者エンゲージメントを向上させます。遠隔医療とデジタルヘルスのプラットフォームは、脂肪肝疾患の管理、患者のケアへのアクセスの改善、継続的な疾患管理のサポートに拡張性と利便性を発揮します。
• 新興市場：医療需要の高まりと認知度の向上を特徴とする新興市場への参入は、大きな成長機会となります。これらの市場は、新薬や医療ソリューションの機が熟しています。新興市場への進出は世界の成長を支え、脂肪肝疾患管理に対する需要の高まりに対応し、世界の健康イニシアチブと医療へのアクセスに合致します。

脂肪肝治療薬市場の戦略的成長手段には、医薬品の進歩、診断サービスの拡大、ライフスタイルプログラム、デジタルヘルス製品、新興市場への参入などが含まれます。患者の生活を向上させ、より良いケアサービスを世界中で提供するために、より多くの治療オプションが開発されているため、市場の将来はこれらの機会の中にあります。

脂肪肝治療薬市場の促進要因・課題

脂肪肝治療薬市場は、非アルコール性脂肪性肝疾患 (NAFLD) と非アルコール性脂肪性肝炎 (NASH) に対する治療法の開発と提供に焦点を当てています。これらの肝臓疾患の有病率が世界的に上昇するにつれ、市場は大きな成長を遂げています。

脂肪肝治療薬市場を牽引する要因は以下の通りである：

1.NAFLDとNASHの有病率の上昇：肥満や糖尿病などの生活習慣病が世界的に増加していることが、効果的な脂肪肝治療薬の需要を促進しています。

2.認知度の向上と診断：認知度の向上と診断技術の改善により、脂肪肝疾患の発見率が高まり、治療需要が高まっています。

3.医薬品開発の進歩：医薬品における継続的な研究開発により、脂肪肝治療薬により効果的な新薬が登場し、市場開拓を後押ししています。

4.医療支出の増加：特に新興国における医療支出の増加は、慢性疾患管理に多くの資源が割り当てられるようになり、脂肪肝治療薬市場の成長を支えています。

5.政府の取り組みと支援：肥満や代謝障害への対処を目的とした政府のプログラムは、関連する健康問題に焦点を当てることで、間接的に脂肪肝治療薬の需要を促進しています。

脂肪肝治療薬市場の課題は以下のとおりである：

1.治療費の高さ：特に低・中所得国では、新たに開発された薬剤や治療法の高額な費用が治療の障壁となり、市場の成長を制限する可能性があります。

2.現在の治療法の副作用と限られた有効性：既存の治療法の多くは副作用が大きかったり、有効性が限定的であったりするため、患者と医療プロバイダーの双方に課題があります。

3.3.NASHに対する承認治療薬の欠如：NASH治療に特化したFDA承認治療薬の欠如は市場にギャップをもたらし、この疾患の管理を妨げています。

4.疾患進行の複雑さ：脂肪肝疾患の進行は多因子性であるため、万能の治療法を開発することは困難であり、薬剤開発の課題となっています。

5.規制上のハードル：医薬品承認に関する厳しい規制要件は、新治療法の市場導入を遅らせ、成長見通しに影響を与える可能性があります。

脂肪肝治療薬市場は、現代人のライフスタイルに関連した肝臓疾患の有病率の上昇と医療意識の高まりにより、成長が見込まれています。しかし、高い治療費、副作用、規制上のハードルといった課題は、市場の潜在力を最大限に引き出すために対処する必要があります。技術革新と的を絞った戦略によってこれらの障害を克服することは、効果的な脂肪肝治療薬に対する需要の高まりに対応し、世界的に患者の転帰を改善する上で極めて重要です。

目次

第1章 エグゼクティブサマリー

第2章 世界の脂肪肝治療薬市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 市場動向と予測分析 (2018年～2030年)

• マクロ経済動向 (2018～2023年) と予測 (2024～2030年)
• 世界の脂肪肝治療薬市場の動向 (2018～2023年) と予測 (2024～2030年)
• 世界の脂肪肝治療薬市場：薬剤別
  • チアゾリジンジオン
  • ビタミンE
  • メトホルミンスタチン
  • 多価不飽和脂肪酸
  • アンジオテンシン受容体拮抗薬
  • ペントキシフィリン
• 世界の脂肪肝治療薬市場：最終用途別
  • 病院
  • クリニック

第4章 地域別の市場動向と予測分析 (2018年～2030年)

• 世界の脂肪肝治療薬市場：地域別
• 北米の脂肪肝治療薬市場
• 欧州の脂肪肝治療薬市場
• アジア太平洋の脂肪肝治療薬市場
• その他地域の脂肪肝治療薬市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 世界の脂肪肝治療薬市場の成長機会：薬剤別
  • 世界の脂肪肝治療薬市場の成長機会：最終用途別
  • 世界の脂肪肝治療薬市場の成長機会：地域別
• 世界の脂肪肝治療薬市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界の脂肪肝治療薬市場の生産能力拡大
  • 世界の脂肪肝治療薬市場における企業合併・買収 (M&A)、合弁事業
  • 認証とライセンシング

第7章 主要企業のプロファイル

• Cardax
• Daewoong
• Hoffmann-La Roche
• Glenmark
• GW Pharmaceuticals

Fatty Liver Treatment Trends and Forecast

The future of the global fatty liver treatment market looks promising with opportunities in the hospital and clinic markets. The global fatty liver treatment market is expected to reach an estimated $26.3 billion by 2030 with a CAGR of 5.3% from 2024 to 2030. The major drivers for this market are the growing alcohol consumption and the increasing prevalence of diabetes.

• Lucintel forecasts that, within the drug category, fatty liver treatment is expected to witness the highest growth over the forecast period.
• Within the end-use category, the hospital is expected to witness a higher growth.
• In terms of regions, North America will remain the largest region over the forecast period due to increasing drug and alcohol abuse along with growing incidence of lifestyle diseases.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Fatty Liver Treatment Market

The fatty liver treatment market is experiencing various emerging trends driven by advancements in medical research, technology, and patient care strategies. These developments are redefining how fatty liver diseases are treated globally.

• Personalized Medicine: Personalized medicine is becoming a dominant trend, where treatments are designed based on individual genetic profiles as well as lifestyle factors. This aims at maximizing therapeutic efficacy while minimizing side effects, making it a more effective method for managing fatty liver disease. Personalized treatments based on patient-specific data offer precise solutions that enhance outcomes and adherence. Genetic research, coupled with data analytics advancements, necessitates such plans, leading to improved treatment interventions.
• Integration of Digital Health Tools: The increasing use of digital health tools, such as mobile applications and wearable devices, allows for tracking patient progress and supporting behavior change management. These tools provide real-time updates about an individual's condition from a healthcare professional's perspective. Digital tools improve patient involvement and adherence to treatment plans while enabling better management of chronic conditions through continuous monitoring and data collection, ultimately improving overall treatment outcomes.
• Advances in Pharmacotherapy: Recent developments in pharmacotherapy include new drug classes and combination therapies targeting liver fat and inflammation. Innovations in drug delivery systems are also enhancing treatment options. New pharmacological treatments provide more effective solutions for managing fatty liver disease, offering additional choices for patients who do not respond well to existing therapies, leading to improved treatment outcomes.
• Focus on Lifestyle Interventions: There is a growing emphasis on incorporating lifestyle interventions, such as diet and exercise, into treatment plans. These interventions are critical for managing and even reversing fatty liver disease. Lifestyle changes play a crucial role in improving liver health and overall well-being. Integrating these interventions with medical treatments enhances patient outcomes and supports long-term disease management.
• Increased Research and Development: Investment in research and development is on the rise, with a focus on discovering new treatments and understanding the underlying mechanisms of fatty liver disease. Increased R&D efforts lead to the development of innovative therapies as well as a better understanding of the condition. This progress contributes to more effective treatments and better patient care.

The emerging trends in the fatty liver treatment market are leading to significant changes in how this condition is managed. Personalized medicine, digital health tools, advances in pharmacotherapy, lifestyle interventions, and increased R&D all contribute to changing treatment approaches, making them more effective and leading to better patient outcomes. These trends highlight enhanced business opportunities for developing individualized treatment methods that can be used holistically to manage fatty liver diseases.

Recent Developments in the Fatty Liver Treatment Market

Recent developments in the fatty liver treatment market reflect ongoing advancements in treatment options, diagnostics, and patient care strategies. These developments signal the future direction for managing fatty liver diseases.

• Approval of New Medications: The introduction of new medications, such as those targeting specific metabolic pathways and liver inflammation, has expanded treatment options. These drugs offer improved efficacy and reduced side effects compared to previous treatments, helping manage fatty liver disease more effectively. They provide additional options for patients who may not have responded to existing treatments, leading to improved overall outcomes.
• Advancements in Diagnostic Technologies: Innovations in imaging and diagnostic technologies, such as enhanced MRI and ultrasound techniques, have improved the accuracy of fatty liver disease assessments. Improved diagnostic tools enable earlier detection and more precise monitoring of disease progression. This advancement supports better treatment planning and management.
• Integration of Lifestyle Management Programs: There is a growing focus on integrating lifestyle management programs, including dietary changes and physical activity, into treatment plans for fatty liver disease. Incorporating lifestyle management enhances the effectiveness of medical treatments and promotes long-term disease reversal. This holistic approach supports overall health and well-being.
• Increased Funding for Research: Increased funding from both government and private sources is supporting research into new treatments and a better understanding of the pathophysiology of fatty liver disease. Enhanced research efforts contribute to the development of innovative therapies and improved disease management strategies. This investment drives progress and better patient outcomes.
• Expansion of Clinical Trials: The number of clinical trials currently being conducted to explore new forms or combinations of treatments for fatty liver disease is increasing. Clinical trials provide crucial information about the effectiveness and safety of new treatments, helping to find solutions that improve patient outcomes.

The fatty liver treatment market is growing due to developments in treatment options, diagnostics, and patient care strategies. The approval of new drugs, the development of diagnostic technologies, integration with lifestyle management, increased funding for research, and expanding clinical trials have shaped the future of fatty liver disease management. There is substantial improvement in treatment efficacy, which has led to better results for patients and illustrates ongoing progress in this field.

Strategic Growth Opportunities for Fatty Liver Treatment Market

Key applications across the fatty liver treatment market offer multiple strategic growth opportunities. These opportunities are underpinned by advances in treatment options, rising patient awareness, and increasing access to healthcare services.

• Pharmaceutical Advancements: Investments in developing novel pharmaceuticals or combination therapies present an excellent growth opportunity. New drug formulations and targeted therapies can result in improved therapeutic effects and more favorable outcomes for patients. Novel pharmaceuticals can provide additional treatment options to address unmet needs within the market, supporting ongoing improvements in disease management and patient care.
• Expansion of Diagnostic Services: Increasing demand for advanced diagnostics, including imaging and lab tests, provides room for expansion. Enhanced diagnostic tools facilitate early identification and accurate monitoring of fatty liver disease, as well as other conditions related to obesity or excessive alcohol use. Increased availability of diagnostic services enables more effective identification and management of fatty liver disease, supporting better treatment planning and improved patient outcomes.
• Lifestyle & Wellness Programs: Integrating lifestyle/wellness programs, such as dietary and exercise interventions, into treatment plans offers potential growth in this area. These programs aid the therapeutic intervention process and contribute to general health promotion activities. Lifestyle and wellness programs offer a more holistic approach to patient care, improving adherence rates and leading to better overall outcomes.
• Telemedicine and Digital Health: The adoption of telemedicine and digital health tools creates opportunities for remote monitoring, patient education, and treatment management. These solutions improve accessibility and patient engagement. Telemedicine and digital health platforms are scalable and convenient for managing fatty liver disease, improving patient access to care, and supporting ongoing disease management.
• Emerging Markets: Entering emerging markets, characterized by growing healthcare demands and increased awareness, presents a significant growth opportunity. These markets are ripe for new drugs and healthcare solutions. Expanding into emerging markets supports global growth and addresses the increasing demand for fatty liver disease management, aligning with global health initiatives and access to care.

Strategic growth avenues in the fatty liver treatment market include advancements in pharmaceuticals, expansion of diagnostic services, lifestyle programs, digital health products, and entry into emerging markets. The future of the market lies within these opportunities, as more treatment options are being developed to enhance patients' lives and provide better care services worldwide.

Fatty Liver Treatment Market Driver and Challenges

The fatty liver treatment market focuses on the development and provision of therapies for Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), conditions characterized by the excessive accumulation of fat in the liver. As the prevalence of these liver conditions rises globally, the market is experiencing significant growth.

The factors driving the fatty liver treatment market include:

1. Rising Prevalence of NAFLD and NASH: The global increase in lifestyle-related conditions like obesity and diabetes is driving the demand for effective fatty liver treatments.

2. Growing Awareness and Diagnosis: Increased awareness and improved diagnostic techniques are leading to higher detection rates of fatty liver conditions, boosting demand for treatments.

3. Advancements in Drug Development: Ongoing research and development in pharmaceuticals are resulting in the introduction of new, more effective drugs for fatty liver treatment, driving market growth.

4. Increasing Healthcare Expenditure: Rising healthcare spending, particularly in emerging economies, is supporting the growth of the fatty liver treatment market as more resources are allocated to chronic disease management.

5. Government Initiatives and Support: Government programs aimed at addressing obesity and metabolic disorders are indirectly driving the demand for fatty liver treatments by focusing on related health issues.

Challenges in the fatty liver treatment market include:

1. High Cost of Treatment: The high cost of newly developed drugs and therapies can be a barrier to treatment, especially in low- and middle-income countries, limiting market growth.

2. Side Effects and Limited Efficacy of Current Therapies: Many existing treatments have significant side effects or limited efficacy, creating challenges for both patients and healthcare providers.

3. Lack of Approved Therapies for NASH: The lack of FDA-approved drugs specifically for NASH treatment creates a gap in the market, hindering the management of this condition.

4. Complexity of Disease Progression: The multifactorial nature of fatty liver disease progression makes it difficult to develop one-size-fits-all treatments, posing challenges for drug development.

5. Regulatory Hurdles: Stringent regulatory requirements for drug approval can delay the introduction of new therapies to the market, affecting growth prospects.

The fatty liver treatment market is poised for growth due to the rising prevalence of liver conditions linked to modern lifestyles and increased healthcare awareness. However, challenges such as high treatment costs, side effects, and regulatory hurdles need to be addressed to unlock the market's full potential. Overcoming these obstacles through innovation and targeted strategies will be crucial in meeting the growing demand for effective fatty liver treatments and improving patient outcomes globally.

List of Fatty Liver Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies fatty liver treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the fatty liver treatment companies profiled in this report include-

• Cardax
• Daewoong
• Hoffmann-La Roche
• Glenmark
• GW Pharmaceuticals

Fatty Liver Treatment by Segment

The study includes a forecast for the global fatty liver treatment by drug, end use, and region.

Fatty Liver Treatment Market by Drug [Analysis by Value from 2018 to 2030]:

• Thiazolidinedione
• Vitamin E
• Metformin Statins
• Polyunsaturated Fatty Acids
• Angiotensin Receptor Blockers
• Pentoxifylline

Fatty Liver Treatment Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospitals
• Clinics

Fatty Liver Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Fatty Liver Treatment Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below are recent developments by fatty liver treatment producers in key regions: the USA, China, India, Japan, and Germany.

• United States: Advanced regulations have led to the approval of new drugs and therapies targeting non-alcoholic steatosis. Notably, the FDA approved a new class of drugs that have shown efficacy in reducing liver fat and inflammation. Additionally, research into personalized care approaches, including lifestyle interventions through digital health tools, is expanding.
• China: In China, there has been a strong push towards integrating traditional Chinese medicine with modern treatments. Recent clinical trials are investigating the effectiveness of herbal supplements combined with conventional therapies. The government is also increasing funding for research on fatty liver disease and promoting public awareness campaigns.
• Germany: In Germany, diagnostic technologies have advanced, improving the accuracy of fatty liver assessments through new imaging techniques. Combination therapies that address both liver fat and metabolic disorders are also being developed. These innovations are gradually being integrated into the national healthcare system.
• India: India has focused on making healthcare more affordable, particularly in rural areas. To lower costs, the country has introduced the production of generic formulations for existing drugs. Public health initiatives are also focused on educating the population about fatty liver disease.
• Japan: Japan has developed new guidelines for managing fatty liver disease that incorporate recent research findings into clinical practice. Furthermore, advanced therapeutics have been adopted, with several clinical trials launched to test new drug candidates and combination therapies.

Features of the Global Fatty Liver Treatment Market

Market Size Estimates: Fatty liver treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Fatty liver treatment market size by drug, end use, and region in terms of value ($B).

Regional Analysis: Fatty liver treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drugs, end uses, and regions for the fatty liver treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the fatty liver treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the fatty liver treatment market by drug (thiazolidinedione , vitamin e, metformin statins, polyunsaturated fatty acids, angiotensin receptor blockers, and pentoxifylline), end use (hospitals and clinics), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Fatty Liver Treatment Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Fatty Liver Treatment Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Fatty Liver Treatment Market by Drug
  • 3.3.1: Thiazolidinedione
  • 3.3.2: Vitamin E
  • 3.3.3: Metformin Statins
  • 3.3.4: Polyunsaturated fatty acids
  • 3.3.5: Angiotensin receptor blockers
  • 3.3.6: Pentoxifylline
• 3.4: Global Fatty Liver Treatment Market by End Use
  • 3.4.1: Hospitals
  • 3.4.2: Clinics

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Fatty Liver Treatment Market by Region
• 4.2: North American Fatty Liver Treatment Market
  • 4.2.1: North American Market by Drug: Thiazolidinedione , Vitamin E, Metformin Statins, Polyunsaturated fatty acids, Angiotensin receptor blockers, and Pentoxifylline
  • 4.2.2: North American Market by End Use: Hospitals and Clinics
• 4.3: European Fatty Liver Treatment Market
  • 4.3.1: European Market by Drug: Thiazolidinedione , Vitamin E, Metformin Statins, Polyunsaturated fatty acids, Angiotensin receptor blockers, and Pentoxifylline
  • 4.3.2: European Market by End Use: Hospitals and Clinics
• 4.4: APAC Fatty Liver Treatment Market
  • 4.4.1: APAC Market by Drug: Thiazolidinedione , Vitamin E, Metformin Statins, Polyunsaturated fatty acids, Angiotensin receptor blockers, and Pentoxifylline
  • 4.4.2: APAC Market by End Use: Hospitals and Clinics
• 4.5: ROW Fatty Liver Treatment Market
  • 4.5.1: ROW Market by Drug: Thiazolidinedione , Vitamin E, Metformin Statins, Polyunsaturated fatty acids, Angiotensin receptor blockers, and Pentoxifylline
  • 4.5.2: ROW Market by End Use: Hospitals and Clinics

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Fatty Liver Treatment Market by Drug
  • 6.1.2: Growth Opportunities for the Global Fatty Liver Treatment Market by End Use
  • 6.1.3: Growth Opportunities for the Global Fatty Liver Treatment Market by Region
• 6.2: Emerging Trends in the Global Fatty Liver Treatment Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Fatty Liver Treatment Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Fatty Liver Treatment Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Cardax
• 7.2: Daewoong
• 7.3: Hoffmann-La Roche
• 7.4: Glenmark
• 7.5: GW Pharmaceuticals